新辅助维莫德吉治疗局部晚期眼周基底细胞癌实现保眼
这项回顾性干预研究纳入2013至2017年接受新辅助维莫德吉后手术的8例T4期眼周基底细胞癌患者,其中6例为复发。中位治疗14个月后全部患者接受保眼手术且切缘阴性,5例完全缓解;末次随访平均18个月时全部无病存活。
要点
- T4期眼周基底细胞癌术前使用维莫德吉可创造保眼手术条件。
- 8例患者全部实现保眼手术且最终手术切缘阴性。
- 5例达完全缓解,3例部分缓解,长期随访仍需确认。
核心结论
- 新辅助维莫德吉使本队列全部T4期眼周基底细胞癌患者得以接受保眼手术。
- 超过半数患者达到完全缓解,手术时未见显微镜下残留肿瘤。
研究设计与样本
- 回顾性干预研究,纳入2013至2017年由同一资深术者治疗的8例T4期眼周基底细胞癌患者。
- 所有患者接受新辅助维莫德吉治疗后行确定性手术,以保眼为主要目标。
主要发现
- 8例中6例为复发性肿瘤,新辅助指征包括1例不可切除、6例为避免眶内容物剜除、1例为避免毁容性面部手术。
- 中位治疗14个月(范围4-36个月),全部患者接受保眼手术且最终切缘阴性。
- 5例完全缓解(手术未见显微镜下残留BCC),3例显著部分缓解(病理见残留肿瘤)。
- 末次随访平均术后18个月(范围6-43个月),全部患者停用维莫德吉且无病存活。
临床怎么用
- 对T4期眼周基底细胞癌,可考虑新辅助维莫德吉后行保眼手术以避免眶内容物剜除。
- 延长治疗多数患者耐受良好,但需仔细长期随访确认无病生存。
局限性
- 回顾性研究、样本量小(8例),随访时间有限,长期无病生存尚需确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIMS: Locally advanced (T4 per American Joint Committee on Cancer (AJCC) 8th edition) periocular basal cell carcinoma (BCC) can lead to loss of the eye. We report the neoadjuvant use of vismodegib followed by surgery in patients with such lesions with eye preservation as primary goal. METHODS: This retrospective interventional study includes all patients with a T4 periocular BCC (per 8th edition AJCC for eyelid carcinoma) treated by the senior author between 2013 and 2017 with neoadjuvant vismodegib prior to definitive surgery. RESULTS: Eight patients had a T4 tumour. Six patients presented with recurrent disease. Indications for neoadjuvant treatment were an unresectable tumour in one patient, an attempt to avoid an orbital exenteration in six patients and an attempt to avoid disfiguring facial surgery in one patient. Patients were treated for a median of 14 months (range: 4-36 months). All patients underwent an eye-sparing surgery following neoadjuvant vismodegib and all final surgical margins were negative for tumour. Five patients had a complete response to vismodegib with no microscopic residual BCC found during surgery; three patients had a significant partial response with residual tumour found on pathology. At last follow-up, a mean of 18 (range: 6-43) months after surgery, all patients were off-vismodegib and alive without evidence of disease. CONCLUSIONS: Neoadjuvant vismodegib for locally advanced (T4) periocular BCC enabled an eye-sparing surgery in all patients in our cohort. Prolonged treatment was well tolerated by most patients. Over half of patients achieved a complete response with no residual microscopic disease. Careful long-term follow-up is needed to confirm long-term disease-free survival.
引用
- Sagiv O, Nagarajan P, Ferrarotto R, et al. Ocular preservation with neoadjuvant vismodegib in patients with locally advanced periocular basal cell carcinoma. Br J Ophthalmol. 2018. PMID: 30021814. doi:10.1136/bjophthalmol-2018-312277
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。